Eli Lilly (LLY) Expands Pipeline with Clazakizumab Agreement, Reuters Reports

Group 1 - Eli Lilly has entered into an agreement with CSL to develop and commercialize clazakizumab, an anti-interleukin-6 monoclonal antibody, with an upfront payment of $100 million to CSL [1][2] - CSL retains exclusive rights to develop and commercialize clazakizumab for preventing cardiovascular events in patients with end-stage kidney disease, while Eli Lilly will focus on other therapeutic areas [2] - Additional payments to CSL may occur based on clinical, regulatory, and commercial milestones, along with royalties from global net sales [2] Group 2 - Eli Lilly has accumulated $1.5 billion in pre-launch inventory for its experimental oral weight-loss drug, orforglipron, ahead of a potential FDA decision expected in April [3][4] - Previously, Eli Lilly reported about $550 million in pre-launch inventory for orforglipron, indicating a significant increase in preparation for the drug's launch [4] - The company aims to have sufficient supply ready for a simultaneous launch across multiple countries if the drug receives regulatory approval [4]